natgillin/translations-raw huggingface dataset:
Abdominalsmerter, dyspepsi, obstipation, diarré, flatulens, øsofageal ulcus*, dysfagi*, abdominal udspiling, syreregurgitation 
Common abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation Uncommon nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena
FOSAVANCE 70 mg/5.600 IE tabletter er modificeret rektangulære, hvide/beige tabletter, der er mærket med omridset af en knogle på den ene side og ”270” på den anden side. 
FOSAVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270' on the other.
FOSAVANCE 70 mg/5.600 IE tabletter EU/1/05/310/006 - 2 tabletter EU/1/05/310/007 - 4 tabletter EU/1/05/310/008 - 12 tabletter 
FOSAVANCE 70 mg/5,600 IU tablets EU/1/05/310/006 - 2 tablets EU/1/05/310/007 - 4 tablets EU/1/05/310/008 - 12 tablets
FOSAVANCE må ikke anvendes under amning. 
FOSAVANCE should not be used during breast-feeding.
EU/1/05/310/006 (2 tabletter) EU/1/05/310/007 (4 tabletter) EU/1/05/310/008 (12 tabletter) 
EU/1/05/310/006 (2 tablets) EU/1/05/310/007 (4 tablets) EU/1/05/310/008 (12 tablets)
FOSAVANCE 70 mg/2.800 IE tabletter 
FOSAVANCE 70 mg/2,800 IU tablets
Hvis du glemmer at tage en tablet, skal du blot tage en FOSAVANCE tablet om morgenen, efter du er kommet i tanke om det. 
If you miss a dose, just take one tablet on the morning after you remember.
Patienter kan opleve visse bivirkninger (f.eks. sløret syn, svimmelhed og svære knogle-, muskel- eller ledsmerter (se pkt. 
Patients may experience certain adverse reactions (for example, blurred vision, dizziness and severe bone muscle or joint pain (see section 4.8)) that may influence the ability to drive and use machines.
FOSAVANCE 70 mg/2.800 IE tabletter er modificeret kapselformede hvide/beige tabletter mærket med omridset af en knogle på den ene side og ”710” på den anden side. 
FOSAVANCE 70 mg/2,800 IU tablets are available as modified capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710' on the other.
EU/1/05/310/003 - 6 tabletter 
EU/1/05/310/003 - 6 tablets
FOSAVANCE 70 mg/5.600 IE tabletter 
FOSAVANCE 70 mg/5,600 IU tablets
Procentdelen af patienter med D-vitaminmangel (serum 25-hydroxyvitamin D < 37,5 nmol/l [<15 ng/ml]) var signifikant reduceret med 62,5 % med FOSAVANCE (70 mg/2.800 IE) versus alendronat alene (henholdsvis 12 % versus 32 %) efter uge 15. 
The percentage of patients with vitamin D insufficiency (serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly reduced by 62.5 % with FOSAVANCE (70 mg/2,800 IU) vs. alendronate-only (12 % vs. 32 %, respectively), through week 15.
EU/1/05/310/004 - 12 tabletter 
EU/1/05/310/004 - 12 tablets
Ved administration af FOSAVANCE 70 mg/5.600 IE tabletter efter en nats faste og to timer før et måltid, var det gennemsnitlige areal under kurven for serum-koncentration-tid (AUC0-80 timer) for D3vitamin (ikke justeret for endogene D3-vitaminniveauer) hos raske voksne forsøgspersoner (mænd og kvinder) 490,2 ngtime/ml. 
In healthy adult subjects (males and females), following administration of FOSAVANCE 70 mg/5,600 IU after an overnight fast and two hours before a meal, the mean area under the serumconcentration-time curve (AUC0-80 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 490.2 ng•hr/ml.
Ved administration af FOSAVANCE 70 mg/2.800 IE tabletter efter en nats faste og to timer før et måltid, var det gennemsnitlige areal under kurven for serum-koncentration-tid (AUC0-120 timer) for D3vitamin (ikke justeret for endogene D3-vitaminniveauer) hos raske voksne forsøgspersoner (mænd og kvinder) 296,4 ngtime/ml. 
In healthy adult subjects (males and females), following administration of FOSAVANCE 70 mg/2,800 IU tablets after an overnight fast and two hours before a meal, the mean area under the serum-concentration-time curve (AUC0-120 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 296.4 ng•hr/ml.
På grund af manglende erfaring bør FOSAVANCE ikke gives til patienter med nedsat nyrefunktion, hvor kreatinin-clearance er <35 ml/min. 
FOSAVANCE is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, due to lack of experience.
EU/1/05/310/002 - 4 tabletter 
EU/1/05/310/002 - 4 tablets
BLISTERTEKST TIL FOSAVANCE 70 mg/2.800 IE 
BLISTER FOR FOSAVANCE 70 mg/2,800 IU
Disse omfatter kunstige fedterstatninger, mineralske olier, slankemidlet orlistat og de kolesterolsænkende lægemidler colestyramin og colestipol. 
It is likely that certain medicines or food additives may prevent the vitamin D in FOSAVANCE from getting into your body, including artificial fat substitutes, mineral oils, the weight loss medicine, orlistat, and the cholesterol-lowering medicines, cholestyramine and colestipol.
BLISTERTEKST TIL FOSAVANCE 70 mg/5.600 IE 
BLISTER FOR FOSAVANCE 70 mg/5,600 IU
FOSAVANCE 70 mg/2.800 IE tabletter Aluminium/aluminiumblisterkort i æsker med 2, 4, 6 eller 12 tabletter. 
FOSAVANCE 70 mg/2,800 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4, 6 or 12 tablets.
Neopharmed Gentili S.r.l. 
MSD Italia S.r.l.
FOSAVANCE 70 mg/5.600 IE tabletter Aluminium/aluminiumblisterkort i æsker med 2, 4 eller 12 tabletter. 
FOSAVANCE 70 mg/5,600 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4 or 12 tablets.
FOSAVANCE 70 mg/2.800 IE, tabletter FOSAVANCE 70 mg/5.600 IE, tabletter 
FOSAVANCE 70 mg/2,800 IU tablets FOSAVANCE 70 mg/5,600 IU tablets
FOSAVANCE 70 mg/5.600 IE tabletter fås i pakninger med 2, 4 eller 12 tabletter. 
FOSAVANCE 70 mg/5,600 IU tablets are available in packs containing 2, 4 or 12 tablets.
Patienter i D3-vitamin 2.800 gruppen fik FOSAVANCE (70 mg/2.800 IE) (n=299), og patienter i D3-vitamin 5.600 gruppen fik FOSAVANCE 
Patients in the Vitamin D3 2,800 group received FOSAVANCE (70 mg/2,800 IU) (n=299) and patients in the Vitamin D3 5,600 group received FOSAVANCE (70 mg/2,800 IU) plus an additional 2,800 IU vitamin D3 (n=309) once a week; additional vitamin D supplements were allowed.
FOSAVANCE 70 mg/2.800 IE tabletter fås i pakninger med 2, 4, 6 eller 12 tabletter. 
FOSAVANCE 70 mg/2,800 IU tablets are available in packs containing 2, 4, 6 or 12 tablets.
Når du har slugt FOSAVANCE tabletten, må du ikke lægge dig ned - du skal forblive oprejst (siddende, stående eller gående) i mindst 30 minutter. 
3) Do not lie down - stay fully upright (sitting, standing or walking) - for at least 30 minutes after swallowing the tablet.
Brug af anden medicin sammen med FOSAVANCE Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Hver FOSAVANCE 70 mg/2.800 IE tablet indeholder 70 mg alendronsyre (som natriumtrihydrat) og 70 mikrogram (2.800 IE) cholecalciferol (D3-vitamin). 
Each FOSAVANCE 70 mg/2,800 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3).
Hver FOSAVANCE 70 mg/5.600 IE tablet indeholder 70 mg alendronsyre (som natriumtrihydrat) og 140 mikrogram (5.600 IE) cholecalciferol (D3-vitamin). 
Each FOSAVANCE 70 mg/5,600 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3).
Sådan skal du tage FOSAVANCE 
How to take FOSAVANCE
Almindelig 
FRI
Det skal du vide, før du begynder at tage FOSAVANCE Sådan skal du tage FOSAVANCE Bivirkninger 
What FOSAVANCE is and what it is used for What you need to know before you take FOSAVANCE How to take FOSAVANCE
Hver tablet indeholder 70 mg alendronsyre (som natriumtrihydrat) og 70 mikrogram (2.800 IE) cholecalciferol (D3-vitamin). 
Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3).
FOSAVANCE 70 mg/2.800 IE tabletter alendronsyre/cholecalciferol 
FOSAVANCE 70 mg/2,800 IU tablets alendronic acid/colecalciferol
Meget sjælden Osteonekrose af øregangen (klassebivirkning for bisphosphonater) 
Very rare osteonecrosis of the external auditory canal
FOSAVANCE 70 mg/5600 IE tabletter alendronsyre/cholecalciferol 
FOSAVANCE 70 mg/5,600 IU tablets alendronic acid /colecalciferol
Asteni 
SAT
I indlægssedlen er der yderligere vigtige informationer om, hvordan du skal tage FOSAVANCE. 
There is important additional information about how to take FOSAVANCE in the package leaflet.
Hver tablet indeholder70 mg alendronsyre (som natriumtrihydrat) og 70 mikrogram (2.800 IE) cholecalciferol (D3-vitamin) 
Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3.
KARTON TIL FOSAVANCE 70 mg/5.600 IE 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR FOSAVANCE 70 mg/5,600 IU
Udseende og pakningsstørrelser 
What FOSAVANCE looks like and contents of the pack
MF (EU)-nummer. 
MA (EU) number
Side 2/2©EMEA 2007 
Page 2/2©EMEA 2006
Dette sammendrag blev sidst ajourført den 9. januar 2007. 
This summary was last updated on 09/01/2007.
Cortavance gives én gang dagligt i 7 dage. 
Cortavance is given once a day for 7 days.
Undgå rygning, når produktet bruges. 
Do not smoke when applying this product.
Er bedring ikke indtrådt efter 7 dage, bør en dyrlæge revurdere behandlingen. 
If no improvement is seen after 7 days, the treatment should be re-evaluated by a veterinarian.
EUROPÆISK OFFENTLIG VURDERINGSRAPPORT (EPAR) CORTAVANCE EPAR - sammendrag for offentligheden 
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) CORTAVANCE EPAR summary for the public
54 hunde blev behandlet med Cortavance, og 51 med det andet produkt. 
Fifty-four dogs were treated with Cortavance and 51 with this other product.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Cortavance til Virback S.A. den 9. januar 2007. 
The European Commission granted a marketing authorisation valid throughout the European Union, for Cortavance to Virback S.A. on 09/01/2007.
Benefit/risk-forholdet fremgår af modul 6 i denne EPAR. 
The benefit-risk balance may be found in module 6 of this EPAR.
De undersøgelser, der skulle fastlægge dosis, underbyggede generelt den valgte dosis og behandlingsvarigheden. 
The studies to determine the dose generally supported the chosen dose and the length of treatment.
Det sprøjtes på det berørte hudområde, idet man undgår at sprøjte i øjnene. 
It is sprayed on the affected area, avoiding the eyes.
Andre oplysninger om Cortavance: 
Other information about Cortavance:
Normalt bør der ikke behandles et større hudareal end svarende til dyrets to sider. 
The treatment area should not normally exceed an area corresponding to the two flanks of the animal.
Der er ikke indberettet bivirkninger hos dyr behandlet med Cortavance. 
There are no side effects reported in animals who have been treated with Cortavance.
Ved uforvarende kontakt (med hud eller øjne), skal stedet afvaskes grundigt med vand. 
In case of accidental contact (skin, eye), wash thoroughly with water.
Steroidet er til stede i en særlig kemisk form (en diester), der bevirker, at det virker på huden selv i lave doser, da det kan trænge ind i det yderste hudlag og forblive der i længere tid. 
The steroid is in a special chemical form (a diester) that makes it effective at low doses in skin conditions as the medicine is able to get into and remain longer in the outer layer of the skin.
Den kliniske del af dokumentationen bestod i undersøgelser til fastlæggelse af dosis og en feltundersøgelse. 
The clinical part of the dossier consisted of studies to determine the dose and of one field trial.
Sprøjtning bør fortrinsvis finde sted i et velventileret lokale. 
Spray preferably in a well ventilated area.
Cortavance er en spray, der indeholder en opløsning af det aktive stof hydrocortisonaceponat. 
Cortavance is a spray containing a solution of the active substance hydrocortisone aceponate.
Før behandlingen skal eventuelle andre hudsygdomme (som f.eks. infektioner) være behandlet, og Cortavance må ikke bruges på hudsår. 
Before treatment, any other existing skin conditions (such as an infection) must be treated and Cortavance should not be used on skin ulcers.
Ved uforvarende indtagelse skal der straks søges lægehjælp, og indlægssedlen eller etiketten skal vises til lægen. 
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician.
Cortavance anvendes til behandling af irriteret og kløende hud hos hunde. 
Cortavance is used to treat inflamed and itchy skin conditions in dogs.
Det aktive stof i Cortavance, hydroxycortisonaceponat, er et steroid, som er en type lægemiddel, der mindsker irritation af vævet. 
The active substance in Cortavance, hydrocortisone aceponate, is a steroid which is a type of substance that helps to reduce inflammation.
Det forklarer, hvordan Udvalget for Veterinærlægemidler (CVMP) vurderede den forelagte dokumentation og nåede frem til sine anbefalinger om, hvordan veterinærlægemidlet skal anvendes. 
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
Sprayflaskens indhold er brandfarligt, og sprayen må ikke anvendes nær åben ild eller gløder. 
The spray is flammable and should not be used next to a naked flame or any incandescent material.
Hvorfor blev Cortavance godkendt? 
Why has Cortavance been approved?
Resultaterne af feltundersøgelsen viser, at virkningen af Cortavance svarer til sammenligningsproduktets. 
Results from the field trial indicated comparable efficacy between Cortavance and the comparator product.
Hvilken risiko er der forbundet med Cortavance? 
What is the risk associated with Cortavance?
Derimod blev væsentlig kløestillende virkning kun påvist i den ene laboratorieundersøgelse, hvor hundene samtidig blev behandlet mod ydre parasitter. 
Significant improvement of the skin condition was demonstrated in several studies under controlled conditions, whereas significant reduction of itching was demonstrated in only one of these laboratory studies in which the dogs received treatment against external parasites at the same time.
En passende mængde til behandling af ca. 100 cm2 hud fås ved to sprøjt med pumpen. 
The pump delivers in two sprays enough medicine to treat an area of about 100 cm2.
Feltundersøgelsen var en multicenterundersøgelse, hvor hunde med kløende hudlidelser blev behandlet enten med Cortavance eller med sammenligningspræparatet, der var et andet steroidholdigt produkt. 
The field trial consisted of a multi-site study comparing treatment of dogs with itchy skin conditions with Cortavance to treatment with a different steroid-containing product.
Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Cortavance opvejer risiciene til behandling af irriteret og kløende hud. 
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Cortavance exceed the risks for the treatment of inflamed and itchy skin conditions and recommended that Cortavance be given a marketing authorisation.
Hvad er Cortavance? 
What is Cortavance?
Normalt bør lægemidlet ikke anvendes til hunde med Cushings syndrom (en sygdom, hvor kroppen producerer for meget naturligt steroid). 
The medicine should not normally be used in dogs suffering from Cushing's syndrome (a disorder where the body produces too much natural steroid), and in young animals (under 7 months of age) as steroids are known to slow growth.
Hvad anvendes Cortavance til? 
What is Cortavance used for?
Hvordan blev Cortavance undersøgt? 
How has Cortavance been studied?
Hvilken fordel viser undersøgelserne, der er ved Cortavance? 
What benefit has Cortavance shown during the studies?
Hvordan virker Cortavance? 
How does Cortavance work?
Følgelig kan en direkte virkning (let toksicitet) eller en indirekte virkning (mindre velsmagende) ikke udelukkes. 
Consequently, a direct effect (slight toxicity), or an indirect effect (low palatability) cannot be excluded.
Visse andre lægemidler kan påvirke brugen af Clopidogrel dura eller omvendt. 
Some other medicines may influence the use of Clopidogrel dura or vice versa.
Hyppighed defineres i henhold til følgende konvention: almindelig (>1/100 til <1/10); ikke almindelig (>1/1.000 til <1/100); sjælden (>1/10.000 til <1/1.000); meget sjælden <1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Kontakt din læge med det samme, hvis De oplever: - feber, tegn på infektion eller udtalt træthed. 
Contact your doctor immediately if you experience: - fever, signs of infection or extreme tiredness.
Ingen af disse analyser var tilstrækkeligt store til at kunne detektere forskelle i outcome hos poor 
None of these analyses were adequately sized to detect differences in outcome in poor metabolisers.
Indehaveren af markedsføringstilladelsen skal fremsende PSUR'er for dette lægemiddel i overensstemmelse med kravene på listen over EU-referencedatoer (EURD list), som fastsat i artikel 107c, stk. 7, i direktiv 2001/83/EF og offentliggjort på den europæiske webportal for lægemidler. 
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines webportal.
Du skal tage Clopidogrel dura, så længe som din læge fortsætter med at ordinere det. 
You should take Clopidogrel dura for as long as your doctor continues to prescribe it.
• hvis du har haft allergi over for eller en reaktion på et lægemiddel, der anvendes til at behandle 
• if you have had an allergy or reaction to any medicine used to treat your disease.
På grund af manglende data kan clopidogrel ikke anbefales i de første 7 dage efter et akut iskæmisk slagtilfælde. 
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke.
Cmax opnås efter ca. 30-60 minutter aefter administration. 
Cmax occurs approximately 30 to 60 minutes after dosing.
Imidlertid er clopidogrel og ASA administreret samtidig i op til et år (se pkt. 
However, clopidogrel and ASA have been administered together for up to one year (see section 5.1).
Blødning er den mest almindeligt rapporterede bivirkning fra både kliniske studier, såvel som fra postmarketing erfaring, hvor den mestendels blev rapporteret i løbet af behandlingens første måned. 
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.
Halveringstiden for elimination af den cirkulerende (inaktive) hovedmetabolit var 8 timer efter en enkelt og efter gentagen administration. 
The elimination half life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Det aktive stof er clopidogrel. 
The active substance is clopidogrel.
• hvis du har haft en blodprop i en blodåre (arterie) i hjernen (iskæmisk apopleksi), inden for de seneste 7 dage 
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days
Dette var ensartet blandt undergrupperne af patienter, defineret ved baseline karakteristika og typen af fibrinolytika eller heparinbehandling. 
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
I COMMIT var den generelle forekomst af non-cerebrale større blødninger eller cerebrale blødninger lav og ensartet i begge grupper. 
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups
Absorptionen er mindst 50% baseret på urinudskillelse af clopidogrels metabolitter. 
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Graviditet og amning Det er bedst ikke at tage denne medicin under graviditet og amning. 
Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy .
Det er usandsynligt, at Clopidogrel dura påvirker din evne til at køre eller betjene maskiner. 
Clopidogrel dura is unlikely to affect your ability to drive or to use machines.
Hos poor metabolisers var eksponeringen nedsat med 63-71 %, sammenlignet med extensive metabolisers. 
In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers.
Den sædvanlige dosis er én tablet Clopidogrel dura à 75 mg dagligt, som tages gennem munden sammen med eller uden mad, og på samme tid hver dag. 
The usual dose is one 75 mg tablet of Clopidogrel dura per day to be taken orally with or without food, and at the same time each day.
Dette skyldes måden din medicin virker på, da den forebygger blodets evne til at danne blodpropper. 
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
Når poor metabolisers fik 600 mg/150 mg regimet, var eksponeringen for den aktive metabolit større end ved 300 mg/75 regimet. 
When poor metabolisers received the 600 mg/150 mg regimen, active metabolite exposure was greater than with the 300 mg/75 mg regimen.
Efter en oral dosis af 14C-mærket clopidogrel hos mennesker blev ca. 50% udskilt i urinen og ca. 46% i fæces i løbet af 120 timer efter dosering. 
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
• skal du fortælle din læge, hvis du skal have foretaget en planlagt operation (herunder 
• You should tell your doctor if a surgery (including dental) is planned.
Hvis du får langvarige blødninger, mens du tager Clopidogrel dura Hvis du skærer dig eller kommer til skade, kan det tage lidt længere end normalt, før blødningen stopper. 
If you experience prolonged bleeding when taking Clopidogrel dura If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Ved steady state var den gennemsnitlige hæmningsgrad, der blev iagttaget med en dosis på 75 mg/dag, mellem 40 % og 60 %. 
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and
Clopidogrel dura indeholder clopidogrel og tilhører en lægemiddelgruppe, der kaldes blodfortyndende medicin. 
Clopidogrel dura contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Hvis du har glemt en dosis af Clopidogrel dura, men kommer i tanke om det i løbet af 12 timer, skal du omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid. 
If you forget to take a dose of Clopidogrel dura, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21 September 2009
TTP er en potentielt letal tilstand, der kræver øjeblikkelig behandling, der omfatter 
TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 patienter): Diarré, mavesmerter fordøjelsesbesvær eller halsbrand. 
Common side effects(may affect up to 1 in 10 people) : Diarrhoea, abdominal pain, indigestion or heartburn.
I et studie af den relative biotilgængelighed hos voksne absorberedes opløsningen af clopidogrel i et lignende omfang og med en lidt højere absorptionsrate af den cirkulerende (inaktive) hovedmetabolit 
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet.
• hvis du har en nyre- eller leversygdom 
• if you have kidney or liver disease.